Skip to main content
Caplight Logo









SURGE Therapeutics

SURGE Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://surgetx.com/

Last Round

Series B

Jul 19, 2023

Total Funding Raised

$58M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

SURGE Therapeutics is a biotechnology company that specializes in a proprietary technology-based platform for delivering localized immunotherapy through an injectable biodegradable hydrogel designed to enhance cancer treatment during surgical tumor resection.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

intraoperative immunotherapyhydrogel drug deliverysolid tumor treatmentcancer recurrence preventionsurgical oncologylocal immunotherapydrug delivery platformclinical-stage biotechlocal drug deliverysurgical site therapyimmuno-oncologybiotech startupdrug-device combination

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SURGE Therapeutics Comparables

Compare SURGE Therapeutics with similar companies based on industry and business-model similarity.

SURGE Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lithea AB
75%
Attivare Therapeutics
73%
OncoLize
72%

SURGE Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 19, 2023
Series AOct 17, 2022

SURGE Therapeutics Investors

Notable investors and investment history

SURGE Therapeutics investors
InvestorRounds
Camford CapitalSeries B, Series A
Bioluminescence VenturesSeries B
Khosla VenturesSeries A, Series B
Intuitive VenturesSeries B, Series A
Cancer Research InstituteSeries A, Series B
8VCSeries A, Series B
Camford CapitalSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 40% MoM.

  • Jul 19, 2023

    $32M round led by Bioluminescence Ventures.

SURGE Therapeutics Filings

Explore SEC and related filing metadata, where available.

SURGE Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SURGE Therapeutics's valuation, stock price, and market status.

Is SURGE a public or private company?

SURGE is a private company.

What is the current stock price of SURGE?

SURGE is a private company with no public stock price. No recent secondary market data is available.

How much is SURGE worth (valuation)?

Valuation information for SURGE is not publicly available.

Can I buy SURGE stock?

SURGE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SURGE's last funding round?

SURGE's most recent funding round was Series B on July 19, 2023.

Who are the main investors in SURGE?

Key investors in SURGE include Camford Capital, Bioluminescence Ventures.

Will SURGE IPO soon?

No public IPO plans have been announced for SURGE.

How can I track SURGE secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SURGE's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range7
Year Founded2018
Last FundingJul 19, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?